2014

Veloxis Pharmaceuticals announces financial results for the first half 2013

HORSHOLM, Denmark, Aug. 21, 2013 /PRNewswire/ --

Highlights:

  • LCP-Tacro™ has successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma) in its Phase III clinical trial, Study 3002. The Phase III randomized, double-blind and double-dummy study in 543 de novo kidney transplant recipients, with Prograf® as the comparator, met its primary efficacy and primary safety endpoints. The study was conducted under a Special Protocol Agreement with the FDA and the results are considered pivotal for the planned U.S. regulatory filing expected to occur in the second half of 2013.

  • The European Medicines Agency (EMA) has accepted for review the company's Marketing Authorization Application (MAA) to market LCP-Tacro™ for the prevention of organ rejection in kidney transplant patients in the European Union. Veloxis expects the decision from the European Union in 2014.

  • Final STRATO clinical study data have demonstrated the potential for LCP-Tacro™ to improve tacrolimus-induced tremors in stable kidney transplant patients.

  • Veloxis reported a net loss of DKK 80.5 million for the first half of 2013 compared to a net loss of DKK 160.6 million for the same period in 2012. The reported net loss is in line with expectations and the financial outlook for 2013 is maintained.

  • For the first half of 2013, Veloxis' research and development costs amounted to DKK 81.7 million compared to DKK 119.5 million during the same period in 2012.

  • On 30 June, 2013, Veloxis had cash and cash equivalents of DKK 399.7 million.

Outlook for 2013
Veloxis maintains its 2013 outlook with an operating and net loss of DKK 170-200 million for the financial year 2013.

As at 30 June 2013, the Company's cash position equaled DKK 399.7 million, and as at 31 December 2013, the Company's cash position is expected to be in the range of DKK 270-310 million.

Conference call
A conference call will be held tomorrow, 22 August, 2013 at 3:00 PM CET (Denmark); 2:00 PM GMT (London), 9:00 AM EDT (New York).

To access the live conference call, please dial one of the following numbers:
+45 32 72 80 18 (Denmark)
+44 (0) 1452 555 131 (UK)
+1 866 682 8490 (USA)
Access code 30348398

Following the conference call, a recording will be available on the company's website http://www.veloxis.com.

Research & development update
LCP-Tacro™ in kidney transplant patients
Veloxis has completed two Phase III studies of LCP-Tacro™ in kidney transplant recipients as the basis for its development programme for LCP-Tacro™ as a once-daily agent for the prophylaxis of organ rejection in kidney transplantation. The first of these studies, the 3001 Study, was a non-inferiority study performed in 326 stable kidney transplant recipients, and was successfully completed in 2011, meeting its primary efficacy and safety endpoints when compared to Prograf® (tacrolimus, Astellas Pharma Inc.). The second study, Study 3002 was a randomized, double-blind, multicenter study that compared once-daily LCP-Tacro™ against twice-daily Prograf® in 543 de novo adult kidney transplant patients and met its primary efficacy and primary safety endpoints. The primary endpoint of the study was a composite endpoint of treatment failure (biopsy-proven acute rejection or BPAR, graft failure, loss to follow up or death) that was evaluated after a 12-month treatment period to demonstrate the non-inferiority of LCP-Tacro™ compared to Prograf®. The treatment failure rate for LCP-Tacro™ was 18.3% compared to 19.6% for Prograf®, well within the 10% pre-specified non-inferiority margin. The primary safety analyses were the differences between LCP-Tacro™ and Prograf® treatment groups at Month 12 (Day 360) with respect to the incidence of adverse events (AEs) and the incidence of predefined potentially clinically significant laboratory measures including: fasting plasma glucose; platelet count; white blood cell (WBC) count; aminotransaminases; total cholesterol; low density lipoprotein (LDL) cholesterol; triglycerides; and estimated glomerular filtration rate (eGFR). In all instances, there were no statistically significant differences between the two treatments. Specifically, renal function was similar between the two groups at 12 months, as was the incidence of malignancy, infections and new onset diabetes during this period. Patients will participate in a 12-month extension period on treatment for follow-up safety assessments.

In addition to the pivotal Phase III studies, Veloxis is planning a series of Phase IIIb/IV studies to further evaluate potential differences in clinical profile provided by LCP-Tacro™'s unique PK profile. The first study initiated is the STRATO (Switching kidney TRAnsplant patients with Tremor to LCP-tacrO) study of LCP-Tacro™ in kidney transplant recipients experiencing drug-induced tremors. The STRATO study was designed to explore whether a conversion of patients who have symptomatic tremor from treatment with standard immediate release twice-daily tacrolimus capsules to extended release once-daily LCP-Tacro™ tablets leads to a measurable improvement in tremor. Results from this study demonstrated that patients switched to LCP-Tacro™ demonstrated a statistically significant improvement in hand tremors based on improvement in the FTM Tremor rating scale. Additionally, both the patient- and physician-reported global assessments demonstrated significant overall improvements following the switch to LCP-Tacro™.

LCP-Tacro™ Regulatory Strategy
On 29 April, 2013 a Marketing Authorization Application (MAA) was submitted by Veloxis to the European Medicines Agency (EMA) seeking approval to market LCP-Tacro™ for the prevention of organ rejection in kidney transplant patients in the European Union. The MAA submission was based on the favorable results of the LCP-Tacro™ Phase III 3001 Study in stable kidney transplant patients and data from an extensive Phase I and II clinical programme and has been accepted for review by the EMA. Veloxis expects to receive a decision on the application in 2014.

The U.S. submission for LCP-Tacro™, for the prophylaxis of organ rejection, to the FDA (Food and Drug Administration) is planned for the second half of 2013 and will include data from the 3002 de novo study in addition to data from Phase I, II and Study 3001.







Financial Highlights















YTD

YTD

Q2

Q2

Year



2013

2012

2013

2012

2012



DKK'000

DKK'000

DKK'000

DKK'000

DKK'000








Income Statement






Revenue

13,736

-

6,868

-

6,868

Research and development costs

(81,719)

(119,487)

(42,772)

(56,639)

(210,739)

Administrative expenses

(14,611)

(19,693)

(6,834)

(9,462)

(36,889)

Operating loss before restructuring cost

(82,594)

(139,180)

(42,738)

(66,101)

(240,760)

Restructuring cost

-

(21,462)

-

(21,462)

(21,462)

Operating loss

(82,594)

(160,642)

(42,738)

(87,563)

(262,222)

Net financial income / (expenses)

1,654

459

(2,253)

2,051

(850)

Loss before tax

(80,940)

(160,183)

(44,991)

(85,512)

(263,072)

Tax for the period

485

(448)

241

(130)

363

Net loss for the period

(80,455)

(160,631)

(44,750)

(85,642)

(262,709)








Balance Sheet






Cash and cash equivalents

399,743

152,720

399,743

152,720

496,834

Total assets

409,371

167,799

409,371

167,799

509,271

Share capital

166,057

45,254

166,057

45,254

165,932

Total equity

334,686

98,968

334,686

98,968

409,737

Investment in property, plant and equipment

-

217

-

126

260








Cash Flow Statement






Cash flow from operating activities

(96,290)

(142,764)

(51,165)

(62,400)

(205,870)

Cash flow from investing activities

-

53,607

-

24,174

169,712

Cash flow from financing activities

(2,506)

(2,395)

(2,555)

(1,085)

404,304

Cash and cash equivalents at period end

399,743

152,720

399,743

152,720

496,834








Financial Ratios






Basic and diluted EPS

(0.05)

(0.35)

(0.03)

(0.19)

(0.43)

Weighted average number of shares

1,660,130,437

452,542,480

1,660,572,426

452,542,480

607,511,489

Average number of employees (FTEs)

28

55

27

55

48

Assets/equity

1.22

1.70

1.22

1.70

1.24


The interim report is unaudited.

Revenue
For the first half of 2013 Veloxis recognized deferred revenue of DKK 13.7 million as revenue compared to no revenue in the same period of 2012. Deferred revenue consist of up-front and milestone payments under Veloxis' distribution agreement with Chiesi Farmaceutici S.p.A. and is recognized in the income statement on a straight line basis based on planned development periods.

Research and development costs
For the first half of 2013, Veloxis' research and development costs amounted to DKK 81.7 million compared to DKK 119.5 million during the same period in 2012. Research and development costs are mainly attributable to the phase III trial in LCP-Tacro™ (de novo patients, Study 3002). The reduction in cost between the two periods is mainly related to effect from the executed restructuring and discontinuation of other pipeline activities in May 2012.

Administrative expenses
For the first half of 2013, Veloxis' administrative cost amounted to DKK 14.6 million compared to DKK 19.7 million during the same period in 2012. The reduction in cost is attributable to the continued focus of reducing overall cost, combined with the effect of the restructuring and reduction in number of employees that took place in May 2012.

Compensation costs
For the first half of 2013, a total of DKK 5.2 million was recognized as share-based compensation. The cost is included in R&D and G&A. The comparable cost for 2012 was DKK 3.5 million.

In the second quarter of 2013, a total of 19,405,513 warrants have been cancelled.

As of 30 June, 2013, there were a total of 85,572,644 warrants outstanding at an average strike price of DKK 0.71. Members of the Board of Directors held 375,941 warrants at an average strike price of DKK 3.35. Members of the Executive Management held 45,631,300 warrants at an average strike price of DKK 0.35, while other current and former employees held 39,565,403 warrants at an average strike price of DKK 1.10.

Please refer to Veloxis' latest annual report for additional details on the Company's warrant programs.

Operating loss
Veloxis' operating loss for the first half of 2013 was DKK 82.6 million compared to DKK 160.6 million in the corresponding period of 2012.

Financial income
During the first half of 2013, the Company recognized net financial income of DKK 1.7 million compared to net financial income of DKK 0.5 million in the corresponding period of 2012. The income is mainly due to currency gain following an increase in the USD / DKK currency rate during the first half of 2013.

Net loss 
Veloxis' net loss for the first half of 2013 was DKK 80.5 million compared to DKK 160.6 million in the corresponding period of 2012.

Cash flow
As per 30 June, 2013, the balance sheet reflects cash and cash equivalents of DKK 399.7 million compared to DKK 496.8 million as per 31 December, 2012. This represents a decrease of DKK 97.1 million primarily related to the Company's operating activities for the period.

Balance sheet
As per 30 June, 2013, total assets were DKK 409.4 million compared to DKK 509.3 million at the end of 2012.

Shareholders' equity equalled DKK 334.7 million as of 30 June, 2013, compared to DKK 409.7 million at the end of 2012.

Significant risks and uncertainties
Veloxis faces a number of risks and uncertainties related to operations, research and development, commercial and financial activities. For further information about risks and uncertainties, we refer to the Annual Report for 2012. As of the date of this Interim Report, there have been no significant changes to Veloxis' overall risk profile since the publication of the Annual Report for 2012.

For more information, please contact:



John D. Weinberg                                  

Johnny Stilou

EVP, Chief Commercial Officer                

EVP, Chief Financial Officer

Mobile: +1 908 304 3389                          

Mobile: +45 21 227 227

Email: jdw@veloxis.com

Email: jst@veloxis.com



The forward looking statements and targets contained herein are based on the current view and assumptions of the Executive Management and the Board of Directors of Veloxis Pharmaceuticals A/S. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Veloxis Pharmaceuticals A/S expressly disclaim any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this interim report to reflect any change in events, conditions, assumptions, or circulations on which any such statements are based unless  required by applicable law.

About LCP‐Tacro™ and tacrolimus
Tacrolimus is a leading immunosuppression drug used for the prevention of transplant allograft rejection after transplantation. LCP-Tacro™ is an investigational drug that is being developed as a once-daily tablet version of tacrolimus with improved bioavailability, consistent pharmacokinetic performance and reduced peak-to-trough variability when compared to currently approved tacrolimus products. Transplant patients need to maintain a minimum blood level of tacrolimus for the prevention of transplant allograft rejection, but excessive levels may increase the risk of serious side effects such as nephrotoxicity, tremor, diabetes, high blood pressure, and opportunistic infections. Therefore, tacrolimus levels need to be managed carefully, and transplant patients are typically obliged to make frequent visits to the hospital for monitoring and dose adjustments after receiving a new organ.

About Veloxis Pharmaceuticals
Based in Horsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is LCP-Tacro™ for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit http://www.veloxis.com.

Executive Management's and the Board of Directors' Statement on the Interim Report

The Executive Management and the Board of Directors have considered and adopted the Interim Report of Veloxis Pharmaceuticals A/S.

The Interim Report is prepared in accordance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and additional Danish disclosure requirements for financial reporting of listed companies.

We consider the applied accounting policies to be appropriate and, in our opinion, the Interim Report gives a true and fair view of the assets and liabilities, financial position, results of the operation and cash flow of the group for the period under review. Furthermore, in our opinion the management review includes a fair review of the development and performance of the business and the financial position of the group, together with a description of the material risks and uncertainties the group faces.

Executive Management



Dr. William J. Polvino

Johnny Stilou

President & CEO

Executive Vice President & CFO                           



Board of Directors




Kim Bjornstrup

Thomas Dyrberg

(Chairman)

(Deputy Chairman)



Anders Gotzsche

Mette Kirstine Agger



 


Financial Highlights








Quarterly Numbers in DKK



















Q2

Q1


Q4

Q3

Q2

Q1



2013

2013


2012

2012

2012

2012



DKK'000

DKK'000


DKK'000

DKK'000

DKK'000

DKK'000










Income Statement








Revenue

6,868

6,868


6,868

-

-

-

Research and development costs

(42,772)

(38,947)


(41,890)

(49,362)

(56,639)

(62,848)

Administrative expenses

(6,834)

(7,777)


(10,235)

(6,961)

(9,462)

(10,231)

Operating loss before restructuring cost

(42,738)

(39,856)


(45,257)

(56,323)

(66,101)

(73,079)

Restructuring cost

-

-


-

-

(21,462)

-

Operating loss

(42,738)

(39,856)


(45,257)

(56,323)

(87,563)

(73,079)

Net financial income / (expenses)

(2,253)

3,907


(2,302)

993

2,051

(1,592)

Loss before tax

(44,991)

(35,949)


(47,559)

(55,330)

(85,512)

(74,671)

Tax for the period

241

244


1,034

(223)

(130)

(318)

Net loss for the period

(44,750)

(35,704)


(46,525)

(55,553)

(85,642)

(74,989)










Balance Sheet








Cash and cash equivalents

399,743

456,216


496,834

86,683

152,720

213,786

Total assets

409,371

465,939


509,271

99,590

167,799

235,187

Share capital

166,057

166,057


165,932

45,254

45,254

452,543

Total equity

334,686

377,276


409,737

42,103

98,968

182,545

Investment in property, plant and

equipment

-

-


43

-

126

91










Cash Flow Statement








Cash flow from operating activities

(51,165)

(45,125)


(399)

(62,707)

(62,400)

(80,364)

Cash flow from investing activities

-

-


56,619

59,486

24,174

29,433

Cash flow from financing activities

(2,555)

48


410,149

(3,450)

(1,085)

(1,310)

Cash and cash equivalents at period end

399,743

456,216


496,834

86,683

152,720

213,786










Financial Ratios








Basic and diluted EPS

(0.03)

(0.02)


(0.08)

(0.12)

(0.19)

(0.17)

Weighted average number of shares

1,660,572,426

1,659,683,537


607,511,489

452,542,480

452,542,480

452,542,480

Average number of employees (FTEs)

27

29


33

49

55

55

Assets/equity

1.22

1.24


1.24

2.37

1.70

1.29

 


Income statement and statement of comprehensive income



Income Statement

Consolidated








(DKK'000)

YTD

YTD

Q2

Q2

Year



2013

2012

2013

2012

2012








Revenue

13,736

-

6,868

-

6,868

Research and development costs

(81,719)

(119,487)

(42,772)

(56,639)

(210,739)

Administrative expenses

(14,611)

(19,693)

(6,834)

(9,462)

(36,889)








Operating loss before restructuring cost

(82,594)

(139,180)

(42,738)

(66,101)

(240,760)








Restructuring cost

-

(21,462)

-

(21,462)

(21,462)








Operating loss

(82,594)

(160,642)

(42,738)

(87,563)

(262,222)








Financial income

9,872

5,226

1,000

3,649

1,481

Financial expenses

(8,218)

(4,767)

(3,253)

(1,598)

(2,331)








Loss before tax

(80,940)

(160,183)

(44,991)

(85,512)

(263,072)








Tax for the period

485

(448)

241

(130)

363








Net loss for the period

(80,455)

(160,631)

(44,750)

(85,642)

(262,709)





























Basic and diluted EPS

(0.05)

(0.35)

(0.03)

(0.19)

(0.43)








Weighted average number of shares

1,660,130,437

452,542,480

1,660,572,426

452,542,480

607,511,489





























Statements of comprehensive income

Consolidated








(DKK'000)

YTD

YTD

Q2

Q2

Year



2013

2012

2013

2012

2012








Net loss for the period

(80,455)

(160,631)

(44,750)

(85,642)

(262,709)

  Other comprehensive income:






  Currency translation differences

(277)

248

(149)

173

427








  Other comprehensive income for the period

(277)

248

(149)

173

427








Total comprehensive income for the period

(80,732)

(160,383)

(44,899)

(85,469)

(262,282)

 


Balance sheet








Assets


Consolidated









(DKK'000)


30 June


30 June


31 Dec.




2013


2012


2012









Patent rights and software


1,981


2,469


2,225









Intangible assets


1,981


2,469


2,225

















Property, plant and equipment


2,634


4,236


2,994

Leasehold improvements


39


200


115









Property, plant and equipment


2,673


4,436


3,109









Non-current assets


4,654


6,905


5,334

















Other receivables


3,964


5,057


5,181

Prepayments


1,010


3,117


1,922









Receivables


4,974


8,174


7,103









Securities


-


112,973


-

Cash


399,743


39,747


496,834









Cash and cash equivalents


399,743


152,720


496,834









Current assets


404,717


160,894


503,937









Assets


409,371


167,799


509,271

 


Balance sheet








Equity & Liabilities


Consolidated









(DKK'000)


30 June


30 June


31 Dec.




2013


2012


2012









Share capital


166,057


45,254


165,932

Special reserve


407,289


407,289


407,289

Translation reserves


2,081


2,179


2,358

Retained earnings/loss


(240,741)


(355,754)


(165,842)









Equity


334,686


98,968


409,737









Finance lease


-


1,718


-









Non-current liabilities


-


1,718


-









Finance lease


721


4,214


3,665

Trade payables


20,179


19,614


18,590

Deferred revenue


34,340


-


48,076

Other payables


19,445


43,285


29,203









Current liabilities


74,685


67,113


99,534









Liabilities


74,685


68,831


99,534









Equity and liabilities


409,371


167,799


509,271

 


Cash flow statements



Cash Flow Statement

Consolidated








(DKK'000)

YTD

YTD

Q2

Q2

Year



2013

2012

2013

2012

2012








Operating loss

(82,594)

(160,642)

(42,738)

(87,563)

(262,222)








Share-based payment

5,243

3,451

2,310

1,891

7,154

Depreciation and amortization

681

8,728

341

7,488

3,391

Impairment loss

-

-

-

-

6,141

Net gain on sale of fixed assets

-

-

-

-

(2,375)

Changes in working capital

(19,587)

5,544

(11,083)

15,670

42,601








Cash flow from operating activities before interest

(96,257)

(142,919)

(51,170)

(62,514)

(205,310)








Interest received

48

962

-

480

1,481

Interest paid

58

(359)

76

(237)

(568)

Corporate tax paid

(139)

(448)

(71)

(129)

(1,473)








Cash flow from operating activities

(96,290)

(142,764)

(51,165)

(62,400)

(205,870)















Purchase of property, plant and equipment

-

(217)

-

(126)

(260)

Sale of property, plant and equipment

-

-

-

-

3,175

Investments in securities

-

(11,935)

-

(8,174)

(19,909)

Sale of securities

-

65,759

-

32,474

186,706








Cash flow from investing activities

-

53,607

-

24,174

169,712















Installments on bank borrowings and finance lease

(2,944)

(2,395)

(2,555)

(1,085)

(4,662)

Proceeds from issuance of shares, net

438

-

-

-

408,966








Cash flow from financing activities

(2,506)

(2,395)

(2,555)

(1,085)

404,304















Increase/(decrease) in cash

(98,796)

(91,552)

(53,720)

(39,311)

368,146

Cash at beginning of period

496,834

130,930

456,216

76,513

130,930

Exchange gains/(losses) on cash

1,705

369

(2,753)

2,545

(2,242)








Cash at end of period

399,743

39,747

399,743

39,747

496,834















Cash and cash equivalents at end of period comprise:













Securities

-

112,973

-

112,973

-

Deposit on demand and cash

399,743

39,747

399,743

39,747

496,834










399,743

152,720

399,743

152,720

496,834

 

Statement of changes in equity










Consolidated Equity











Number of

Shares


Share

Capital

Share

Premium

Special

Reserves

Translation

Reserves

Retained

Earnings

Total





DKK'000

DKK'000

DKK'000

DKK'000

DKK'000

DKK'000











Equity as of 1 January 2012

452,542,480


452,543

-

-

1,931

(198,574)

255,900











Total comprehensive income






248

(160,631)

(160,383)











Reduction of share capital



(407,289)


407,289



-

Share-based payment







3,451

3,451











Equity as of 30 June 2012

452,542,480


45,254

-

407,289

2,179

(355,754)

98,968











Total comprehensive income






179

(102,078)

(101,899)











Issuance of shares

1,206,779,946


120,678

301,695




422,373

Share-based payment







3,703

3,703

Costs related to capital increases



(13,408)




(13,408)

Transfer of retained earnings




(288,287)



288,287

-











Equity as of 31 December 2012

1,659,322,426


165,932

-

407,289

2,358

(165,842)

409,737











Total comprehensive income






(277)

(80,455)

(80,732)











Warrant exercises

1,250,000


125

313




438

Share-based payment







5,243

5,243

Transfer of retained earnings




(313)



313

-











Equity as of 30 June 2013

1,660,572,426


166,057

-

407,289

2,081

(240,741)

334,686

 

Notes

1.         Accounting policies
The interim report is prepared in compliance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and in accordance with the NASDAQ OMX Copenhagen's financial reporting requirements for listed companies.

There have been no changes in accounting policies used for the interim report compared to the accounting policies used in the preparation of Veloxis Pharmaceuticals' annual report for 2012.

 

SOURCE Veloxis Pharmaceuticals



RELATED LINKS
http://www.veloxis.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.